Forest Laboratories, Inc. (FRX) Pursues Additional Market Exclusivity To Extend Namenda Patent
1/13/2014 10:22:15 AM
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) announced today that it has submitted to the Food and Drug Administration (FDA) data from its pediatric program to extend the Namenda (memantine HCI) U.S. patent 5,061,703.
Help employers find you! Check out all the jobs and post your resume.
comments powered by